AstraZeneca’s fixed-duration Calquence combo succeeds in Phase 3 blood cancer test

Ayisha Sharma

News Reporter

When given with other cancer drugs for a limited time, AstraZeneca’s Calquence hit the primary endpoint in a registrational test, which could open up a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AstraZeneca’s fixed-duration Calquence combo succeeds in Phase 3 blood cancer test

Ayisha Sharma

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma companies rush in to buy what they hope will rival Keytruda

BioNTech presents impressive early data for PD-L1xVEGF in mesothelioma

New CBER chief Prasad promises to 'rapidly' push even small advances for rare disease drugs

At ASCO, cell therapies for deadly form of brain cancer make early strides

Agenus quickly exits CDMO business by selling assets to Zydus for $75M upfront

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

As­traZeneca’s fixed-du­ra­tion Calquence com­bo suc­ceeds in Phase 3 blood can­cer test

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca’s fixed-duration Calquence combo succeeds in Phase 3 blood cancer test